Pharmacokinetic interaction between methotrexate and piperacillin/ tazobactam resulting in prolonged toxic concentrations of methotrexate [9]

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 228-230

  Zarychanski, Ryan ^a   Wlodarczyk, K ^a   Ariano, R ^a   Bow, E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cytotoxic; Human organic anion transporters; Impaired elimination

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PIPERACILLIN PLUS TAZOBACTAM; VINCRISTINE;

ADULT; BURKITT LYMPHOMA; CASE REPORT; CLINICAL PROTOCOL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG POTENTIATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LETTER; LONG TERM CARE; PNEUMONIA; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN;

EID: 33748065311     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl196     Document Type: Letter

References (6)

1. Crom WR, Evans W. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA: Applied Therapeutics, Inc., 1992; 1-42.
2. Aheme GW, Marks V, Mould GP et al. The interaction between methotrexate and probenecid in man [proceedings]. Br J Pharmacol 1978; 63: 369P.
3. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992; 26: 234-7.
4. Williams WM, Chen TS, Huang KC. Effect of penicillin on the renal tubular secretion of methotrexate in the monkey. Cancer Res 1984; 44: 1913-7.
5. Iven H, Brasch H. Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits. Cancer Chemother Pharmacol 1986; 17: 218-22.
6. Yamamoto K, Sawada Y, Matsushita Y et al. Delayed elimination of methotrexate associated with piperacillin administration. Ann Pharmacother 1997; 31: 1261-2.